BioMed Research International

Research Article

Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study

Table 4

Clinical data on patients with SPECT shown per SPECT time-point.
  PDMSAPSP
SPECT
year		DAT IBZMDAT IBZM DAT IBZM
  Mean95% CIMean95% CIMean95% CIMean95% CIMean95% CIMean95% CI
Age 074.472.8–76.074.572.9–76.171.360.7–81.969.957.4–82.375.971.3–80.675.370.4–80.2
175.573.9–77.175.573.9–77.176.373.3–79.276.273.4–79.074.370.5–78.173.869.2–78.5
377.375.5–79.177.575.8–79.378.775.9–81.577.574.7–80.372.5 61–8475.968.1–83.7
Duration01.51.2–1.81.61.2–1.91.30.6–2.01.50.7–2.31.91.1–2.71.81.0–2.7
12.62.3–3.02.62.3–3.03.12.2–4.03.02.1–3.92.91.9–3.92.81.6–4.0
34.54.1–4.94.43.9–4.85.14.1–6.25.54.1–6.84.60.3–9.05.03.1–6.9
LED00.00.0–0.00.00.0–0.00.00.0–0.00.00.0–0.00.00.0–0.00.00.0–0.0
1335273–397335273–397312160–465312160–465340157–522287108–467
3507.4419–595439352–526582404–761620398–842708202–121451592–938
  MedianMin–MaxMedianMin–MaxMedianMin–MaxMedianMin–MaxMedianMin–MaxMedianMin–Max
UPDRS-III0278–46278–46229–4822.521–483012–642912–64
1253–48253–482414–442414–4436†18–5435.5††18–54
3253–48236–5441*31–6541.0*33–4948† 43††38–55
UPDRS% Change during first year ( ) Median −7.7
Min −87–Max 52.9		 ( ) Median 8.9* 
Min −22.5–Max 55.6		 ( ) Median 42.3†† 
Min 2.4–Max 77.8
H&Y 021–321–322–522–52.51.5–52.51.5–5
121–321–322–322–32.75†1.5–52.75††2–5
322–422–33*2–53*2–44†2–52.5†2–5
ADL%09060–959060–959060–1009060–1008070–958070–95
19060–959060–959070–909070–9080†50–9580††50–95
39040–1009040–10080*40–8080*70–807030–907030–90
Mann-Whitney U test: *PD versus MSA: ; †PD versus PSP: ; ††PD versus PSP: ; †††PD versus PSP: . year: 0: baseline, 1: first year, 3: third year; LED: L-Dopa equivalent dose index; UPDRS-III: Unified Parkinson’s Disease Rating Scale, motor examination; H&Y: Hoehn and Yahr stage; ADL: Activities of daily living scale; 95% CI: 95% confidence interval.